Patents by Inventor Dinah W. Y. Sah

Dinah W. Y. Sah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL NEUROTROPHIC FACTORS
    Publication number: 20080233647
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: February 12, 2008
    Publication date: September 25, 2008
    Applicants: BIOGEN IDEC MA INC., NSGENE A/S
    Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Methods of treating pain using neurotrophic factors
    Patent number: 7358228
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: April 15, 2008
    Assignees: Biogen Idec MA Inc., NsGene A/S
    Inventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Neurotrophic factors
    Patent number: 7276580
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: October 2, 2007
    Assignees: Biogen Idec MA Inc., NsGene A/S
    Inventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Nogo receptor homologs
    Patent number: 7173118
    Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: February 6, 2007
    Assignees: Biogen Idec MA Inc., Yale University
    Inventors: Stephen M. Strittmatter, Richard L. Cate, Dinah W. Y. Sah
  • Human mesencephalon cell lines and methods of use therefor
    Patent number: 6913925
    Abstract: Conditionally-immortalized human mesencephalon cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons, including dopaminergic neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of neurological diseases such as Parkinson's disease. The cell lines and/or differentiated cells may also be used in assays and for the general study of mesencephalon cell development and differentiation.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: July 5, 2005
    Assignee: Signal Pharmaceuticals LLC
    Inventors: Dinah W. Y. Sah, Heather K. Raymon
  • PNS cell lines and methods of use therefor
    Patent number: 6835567
    Abstract: Conditionally-immortalized PNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of PNS-related diseases. The cell lines and/or differentiated cells may also be used in assays and for the general study of PNS cell development, death and abnormalities.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: December 28, 2004
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Dinah W. Y. Sah, Heather K. Raymon
  • Novel neurotrophic factors
    Publication number: 20040142418
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: September 12, 2003
    Publication date: July 22, 2004
    Inventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Treatment using neublastin polypeptides
    Publication number: 20040077543
    Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
    Type: Application
    Filed: September 24, 2003
    Publication date: April 22, 2004
    Inventor: Dinah W. Y. Sah
  • Human CNS cell lines and methods of use therefor
    Patent number: 6713247
    Abstract: Conditionally-immortalized human CNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons and/or astrocytes. Such cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of CNS-related diseases. Such cell lines and/or differentiated cells may also be used in assays and for the general study of CNS cell development, death and abnormalities.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: March 30, 2004
    Assignee: Signal Pharmaceuticials, Inc.
    Inventors: Dinah W. Y. Sah, Fred H. Gage, Jasodhara Ray
  • Nogo receptor homologs
    Publication number: 20030124704
    Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
    Type: Application
    Filed: October 6, 2001
    Publication date: July 3, 2003
    Inventors: Stephen M. Strittmatter, Richard L. Cate, Dinah W. Y. Sah
  • Human spinal cord cell lines and methods of use therefor
    Patent number: 6225122
    Abstract: Conditionally-immortalized human spinal cord cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons, including motoneurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of spinal cord-related diseases and injuries. The cell lines and/or differentiated cells may also be used in assays and for the general study of spinal cord cell development and differentiation.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: May 1, 2001
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Dinah W. Y. Sah, Ronghao Li